OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Braun on Unanswered Questions With PD-1 Blockade in Advanced RCC

July 28th 2020

David A. Braun, MD, PhD, discusses unanswered questions regarding the utility of PD-1 blockade in advanced renal cell carcinoma.

Dr. Palmer on the Incidence of Graft-Versus-Host Disease

July 28th 2020

Jeanne M. Palmer, MD, discusses the prognosis and challenges of predicting graft-versus-host disease in patients who have undergone transplant.

Dr. Gafita on the Opportunity for 177Lu-PSMA-617 in mCRPC

July 28th 2020

Andrei Gafita, MD, discusses available therapies for men with advanced castration-resistant prostate cancer.

Dr. Roland on Neoadjuvant Checkpoint Blockade in Sarcoma Subtypes

July 28th 2020

Christina L. Roland, MD, PhD, discusses the design of a randomized, phase 2 trial with nivolumab and ipilimumab in resectable retroperitoneal dedifferentiated liposarcoma, as well as radiation therapy in extremity/truncal undifferentiated pleomorphic sarcoma.

Dr. Zakashansky on Maintenance Olaparib in Relapsed BRCA1/2+ Ovarian Cancer

July 28th 2020

Konstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.

Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases

July 28th 2020

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the prognosis of patients with melanoma brain and/or central nervous system metastases.

Dr. Lenz on Later-Line Combo Approaches in CRC

July 28th 2020

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment combination approaches in colorectal cancer.

Dr. Reck on Safety Data From the CheckMate-9LA Trial in Metastatic/Recurrent NSCLC

July 24th 2020

Martin Reck, MD, PhD, discusses safety data from the phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Dr. Ramalingam on Next Steps With Nivolumab/Ipilimumab in NSCLC

July 24th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the utility of nivolumab plus ipilimumab in metastatic or recurrent non–small cell lung cancer.

Dr. Ahn on Limitations of Targeted Therapy in CRC

July 24th 2020

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Dr. Shafique on the Goal of the CLASSICAL-Lung Trial With Pepinemab/Avelumab in NSCLC

July 24th 2020

Michael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.

Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL Models

July 24th 2020

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Dr. Monk on the Limitations of Current Treatment in Metastatic/Recurrent Cervical Cancer

July 24th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

Dr. Chandra on Unanswered Questions With Targeted Therapy in Melanoma

July 24th 2020

Sunandana Chandra, MD, MS, discusses unanswered questions regarding the utility of targeted therapy in melanoma.

Dr. Wang on the FDA Approval of Brexucabtagene Autoleucel in MCL

July 24th 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

Dr. Hope on Challenges With 68Ga-PSMA-11 PET in Prostate Cancer

July 23rd 2020

Thomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.

Dr. Ghosh on Safety Results From the Phase 2 PILOT Trial in Non-Hodgkin Lymphoma

July 23rd 2020

Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.

Dr. Shah on Updated Results With Trastuzumab Deruxtecan in DESTINY-Gastric01

July 23rd 2020

Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.

Dr. Lenz on Choosing Between Regorafenib and TAS-102 in CRC

July 23rd 2020

Heinz-Josef Lenz, MD, FACP, discusses factors to consider when choosing between regorafenib and trifluridine/tipiracil in the third-line treatment of patients with colorectal cancer.

Dr. Ajani on Clinical Implications of Trastuzumab Deruxtecan in Gastric and GEJ Adenocarcinoma

July 23rd 2020

Jaffer A. Ajani, MD, discusses the potential clinical implications of fam-trastuzumab deruxtecan-nxki in gastric or gastroesophageal junction adenocarcinoma if approved by the FDA.